Fig. 1From: Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorinProgression-free survival (A) and overall survival (B) in patients treated with nanoliposomal irinotecan plus 5-FU/LV (fluorouracil/leucovorin)Back to article page